How DMPK should integrate with and influence projects in discovery and beyond
Meet Dr. Richard Weaver, Senior VP of Preclinical Development, a visionary in the field. Delve into the realm of pre-clinical candidates and their often concealed structural flaws. These challenges, including solubility issues, ambitious human dose projections, bioavailability hurdles, safety margins, target engagement dilemmas, and PK/PD complexities, underscore the critical need for early DMPK scientist involvement.
Embark on a captivating journey as Richard unravels DMPK’s pervasive impact, extending from Drug Discovery’s inception to its far-reaching horizons. Explore the labyrinth of pitfalls, untangle misconceptions, and absorb invaluable advice, all meticulously curated to chart a course towards unparalleled success in drug development. This is an opportunity to glean insights, fine-tune strategies, and harness DMPK’s potential for transformative outcomes.